Lipocine Initiates Pivotal Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine Inc. announced the initiation of its BLOOM Phase 3 clinical study for LPCN 1154, an investigational oral treatment for postpartum depression (PPD). The study is designed to generate the necessary efficacy and safety data to support a potential New Drug Application (NDA). LPCN 1154 is being developed as a 48-hour, at-home treatment to provide rapid symptom relief.

Key Details

• Study Design: The BLOOM study will enroll approximately 120 participants with severe PPD and incorporates feedback from the FDA and learnings from a prior Phase 3 trial.
• Timeline & Financials: First participant dosing is expected in early Q4 2026. The company believes its existing cash of $23.3 million (as of June 30, 2026) is sufficient to fund the study, with an expected cash use of approximately $1 million per month during execution.
• Background: The new trial follows a previous Phase 3 study that did not meet its primary endpoint due to identified anomalies at a high-enrolling site. Exploratory analysis excluding that site suggested rapid and sustained improvement in depressive symptoms.